

VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center	Issue Date: 20 Aug 2014	Document: MR-590.03
Authorized by: Jan Hickey CHIEF, CMS	Version: 1	Page 1 of 7
Sub Authorizer: Stanley JOHNSON CHIEF, QUALITY CONTROL SECTION		
Document Title: Overcoating Lithium 300 mg Placebo Tablets in the O'Hara Labcoat M 15" Pan		
INVALID 2 WKS FROM PRINT DATE	Print Date: 7/27/15	

MANUFACTURING PROCEDURES

CSP 590	Production Run (Batch/Lot) #: _____	Theoretical Lot Size ¹ : _____ kg/batch	Start Time: _____ Start Date: _____
MPR #: _____	TID #: _____	Theoretical # units/batch ² : _____	End Time: _____ End Date: _____

¹Batch size to be determined at time of manufacture (Procedures suitable for 1.5 Kg to 3.375 Kg batches)

²Theoretical No. of Tablets to be calculated at time of production (batch size divided by 0.375)

Component ID, Weights and Measures Log

COMPONENT	TID	QUANTITY PER TABLET	FORMULA =	BULK QTY REQUIRED	QUANTITY ON HAND	CALC. PERFORMED BY	CALC. CHECKED BY	QM CHECK
PLACEBO 375 mg MYTHICAL tablets		1	Desired batch size (in Kg) X 1,000	_____g	_____g			
Opadry II orange (85F93265)		11.25 mg (3% of tab wt)	Batch size x 0.03*	_____g	_____g			
DI Water		N/A	Weight of Opadry required x 5	_____g	_____g			

*Target 3% weight gain

Step #:	Procedure Description	Specification – Tolerances	Value	Performed By:	Checked By:
	Safety Precautions: normal personal protective gear; no special safety precautions required.				

VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center		Issue Date: 20 Aug 2014	Document: MR-590.03
Authorized by: Jan Hickey CHIEF, CMS		Version: 1	Page 2 of 7
Sub Authorizer: Stanley JOHNSON CHIEF, QUALITY CONTROL SECTION			
Document Title: Overcoating Lithium 300 mg Placebo Tablets in the O'Hara Labcoat M 15" Pan			
INVALID 2 WKS FROM PRINT DATE		Print Date: 7/27/15	

MANUFACTURING PROCEDURES

Step #:	Procedure Description	Specification – Tolerances	Value	Performed By:	Checked By:
1	<p>Manually verify the calibration of each balance to be used with a set of certified masses prior to weighing active ingredient or excipients.</p> <ul style="list-style-type: none"> Only use scales calibrated for the unit of measure to be weighed <ul style="list-style-type: none"> i.e. Kg scale for Kg weight, mg scale for mg weight, g scale for g weight. Use one certified mass for each scale that weighs less than the lowest value to be weighed on that scale. Use one certified mass for each scale that weighs more than the heaviest value to be weighed on that scale. Attach a printout of the results to this page. Actual results shall fall within $\pm 0.5\%$ of the test mass. 	<p>Mettler Toledo</p> <p>No. _____</p> <p>Certified Low Mass Weight:</p> <p>_____g</p> <p>Certified High Mass Weight:</p> <p>_____g</p>	<p>Low Mass Range:</p> <p>Low: _____ g</p> <p>High: _____ g</p> <p>Actual: _____ g</p> <p>High Mass Range:</p> <p>Low: _____ g</p> <p>High: _____ g</p> <p>Actual: _____ g</p>		
2	<p>Weigh _____ g of Opadry.</p> <p>Record actual weight.</p> <p>Acceptable range $\pm 1\%$ of the bulk quantity determined in the Component ID, Weights and Measures Log</p>	<p>Minimum : _____g</p> <p>to</p> <p>Maximum: _____g</p>	<p>ACTUAL WEIGHT OF OPADRY:</p> <p>_____g (A)</p>		

VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center		Issue Date: 20 Aug 2014	Document: MR-590.03
Authorized by: Jan Hickey CHIEF, CMS		Version: 1	Page 3 of 7
Sub Authorizer: Stanley JOHNSON CHIEF, QUALITY CONTROL SECTION			
Document Title: Overcoating Lithium 300 mg Placebo Tablets in the O'Hara Labcoat M 15" Pan			
INVALID 2 WKS FROM PRINT DATE		Print Date: 7/27/15	

MANUFACTURING PROCEDURES

Step #:	Procedure Description	Specification – Tolerances	Value	Performed By:	Checked By:
3	Weigh _____ g of DI water. Record actual weight. Acceptable range ± 0.1 g of the bulk quantity determined in the Component ID, Weights and Measures Log	Minimum : _____g to Maximum: _____g	ACTUAL WEIGHT OF DEIONIZED WATER: _____g		
4	Using the variable-blade standard mixer, slowly add the Opadry powder to the water from step 3. Mix for at least 45 minutes prior to initiation of spraying. Continue mixing throughout the coating process to prevent sedimentation.	Required mix time: ≥ 45 minutes	Start Time: _____ Stop Time: _____ Total Mixing Time before initiating spraying: _____min.		
5	Weigh _____ g of tablets. Record actual weight. Acceptable range ± 200 g of the bulk quantity determined in the Component ID, Weights and Measures Log	Minimum : _____g to Maximum: _____g	ACTUAL WEIGHT OF UNCOATED TABLETS: _____g (B)		
6	Place tablets in the O'Hara Labcoat M 15 inch pan..				

VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center		Issue Date: 20 Aug 2014	Document: MR-590.03
Authorized by: Jan Hickey CHIEF, CMS		Version: 1	Page 4 of 7
Sub Authorizer: Stanley JOHNSON CHIEF, QUALITY CONTROL SECTION			
Document Title: Overcoating Lithium 300 mg Placebo Tablets in the O'Hara Labcoat M 15" Pan			
INVALID 2 WKS FROM PRINT DATE		Print Date: 7/27/15	

MANUFACTURING PROCEDURES

Step #:	Procedure Description	Specification – Tolerances	Value	Performed By:	Checked By:
7	<p>Turn on O'Hara coating apparatus and set processing parameters at the following settings:</p> <ul style="list-style-type: none"> • Inlet temperature: 62 - 65°C • Inlet air volume: 160 cfm • Pan pressure (INWC): -10.0 -14.0 • Pan speed: 20 RPM (adjust if necessary to achieve an even mixing of the tablet bed) • Pan jog: 15 RPM • Pump speed: 15 - 20 grams/minute • Atomizing air: 10 – 15 psi • Pattern air: 15 – 22 psi <p>Note that these are initial settings and may need to be adjusted during the coating process as described in step 8.</p>				

VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center		Issue Date: 20 Aug 2014	Document: MR-590.03
Authorized by: Jan Hickey CHIEF, CMS		Version: 1	Page 5 of 7
Sub Authorizer: Stanley JOHNSON CHIEF, QUALITY CONTROL SECTION			
Document Title: Overcoating Lithium 300 mg Placebo Tablets in the O'Hara Labcoat M 15" Pan			
INVALID 2 WKS FROM PRINT DATE		Print Date: 7/27/15	

MANUFACTURING PROCEDURES

Step #:	Procedure Description	Specification – Tolerances	Value	Performed By:	Checked By:
8	<p>Begin the coating process.</p> <p>Ensure spray nozzle is tilted to spray the upper third of the tablet bed.</p> <p>Adjust atomization air pressure if needed to create a fine mist.</p> <p>Adjust spray rate if necessary to prevent tablet sticking (to the pan or to each other) and spray drying.</p> <p>If necessary, adjust pan speed to ensure even mixing of the tablet bed.</p> <p>Record all changes on the addendum page.</p> <p>Continue spraying until all Opadry suspension has been sprayed.</p>				
9	Pump DI water through the tubing for 2-3 minutes.	Required time = 2-3 minutes	Start Time: _____ Stop Time: _____ Total Spraying Time: _____min.		
10	Allow tablets to continue to tumble in the drum for an additional 4-5 minutes to ensure some degree of dryness has been achieved.	Required time = 4-5 minutes	Start Time: _____ Stop Time: _____ Total Spraying Time: _____min.		

VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center		Issue Date: 20 Aug 2014	Document: MR-590.03
Authorized by: Jan Hickey CHIEF, CMS		Version: 1	Page 6 of 7
Sub Authorizer: Stanley JOHNSON CHIEF, QUALITY CONTROL SECTION			
Document Title: Overcoating Lithium 300 mg Placebo Tablets in the O'Hara Labcoat M 15" Pan			
INVALID 2 WKS FROM PRINT DATE		Print Date: 7/27/15	

MANUFACTURING PROCEDURES

Step #:	Procedure Description	Specification – Tolerances	Value	Performed By:	Checked By:
11	Record total coating time.		TOTAL COATING TIME: _____min.		
12	Remove the coated tablets from the drum. Weigh coated tablets and record actual weight.		ACTUAL WEIGHT OF COATED TABLETS: _____g (C)		
13	Calculate a percent weight gain for the batch. [Weight of coated tablets (C)] divided by weight of uncoated tablets B (C) ÷ (B) = _____ (D) Determine the theoretical weight gain. Weight of uncoated tablets (B) x 1.03 = _____(E) Calculate the % of theoretical.	Acceptable range: 85-105% of theoretical	PERCENT YIELD (% of theoretical weight gain): _____(D) _____(E) x100 = _____%		
14	Visually examine the coated tablets. Set aside any chipped or damaged tablets for additional coating or destruction.				

VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center	Issue Date: 20 Aug 2014	Document: MR-590.03
Authorized by: Jan Hickey CHIEF, CMS	Version: 1	Page 7 of 7
Sub Authorizer: Stanley JOHNSON CHIEF, QUALITY CONTROL SECTION		
Document Title: Overcoating Lithium 300 mg Placebo Tablets in the O'Hara Labcoat M 15" Pan		
INVALID 2 WKS FROM PRINT DATE	Print Date: 7/27/15	

MANUFACTURING PROCEDURES

Step #:	Procedure Description	Specification – Tolerances	Value	Performed By:	Checked By:
15	Double bag and quarantine coated tablets until released by QCS				
16	Enter final inventory in DOSE.				